دورية أكاديمية
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
| العنوان: | Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results |
|---|---|
| المؤلفون: | Salazar Soler, Ramón, Capdevila, Jaume, Manzano, José Luis, Pericay, Carles, Martínez Villacampa, Mercedes, López, Carlos, Losa, Ferrán, Safont, María José, Gómez Espana, Auxiliadora, Alonso Orduña, Vicente, Escudero, Pilar, Gallego, Javier, García Paredes, Beatriz, Palacios, Amalia, Biondo, Sebastián, Grávalos, Cristina, Aranda, Enrique, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) |
| المصدر: | Articles publicats en revistes (Ciències Clíniques) |
| بيانات النشر: | BioMed Central |
| سنة النشر: | 2020 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Càncer colorectal, Quimioteràpia, Radioteràpia, Colorectal cancer, Chemotherapy, Radiotherapy |
| الوصف: | Background: Preoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The “Tratamiento de Tumores Digestivos” group (TTD) previously reported in a randomized Ph II study that the addition of Bevacizumab to capecitabine-RT conferred no differences in the pre-defined efficacy endpoint (pathological complete response). We present the follow-up results of progression-free survival, distant relapse-free survival, and overall survival data at 3 and 5 years. Methods: Patients (pts) were randomized to receive 5 weeks of radiotherapy (45 Gy/25 fractions) with concurrent Capecitabine 825 mg/m2 twice daily, 5 days per week with (arm A) or without (arm b) bevacizumab (5 mg/kg once every 2 weeks). Results: In our study, the addition of bevacizumab to capecitabine and radiotherapy in the neoadjuvant setting shows no differences in pathological complete response (15.9% vs 10.9%), distant relapse-free survival (81.0 vs 80.4 and 76.2% vs 78.2% at 3 and 5 years respectively), disease-free survival (75% vs 71.7 and 68.1% vs 69.57% at 3 and 5 years respectively) nor overall survival at 5-years of follow-up (81.8% vs 86.9%). Conclusions: the addition of bevacizumab to capecitabine plus radiotherapy does not confer statistically significant advantages neither in distant relapse-free survival nor in disease-free survival nor in Overall Survival in the short or long term. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 11 p.; application/pdf |
| اللغة: | English |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1186/s12885-020-07661-zTest; BMC Cancer, 2020, vol. 20; https://doi.org/10.1186/s12885-020-07661-zTest; http://hdl.handle.net/2445/173783Test; 709274 |
| الإتاحة: | https://doi.org/10.1186/s12885-020-07661-zTest http://hdl.handle.net/2445/173783Test |
| حقوق: | cc by (c) Salazar Soler et al., 2020 ; http://creativecommons.org/licenses/by/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.A596A0E |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |